IPH Limited Overview
IPH Limited is the largest listed intellectual property (IP) services group globally that focuses on secondary IP markets. These are jurisdictions where multinational innovators seek patent and trade mark protection after filing in their home market. Through member firms Spruson & Ferguson, Griffith Hack (which absorbed Pizzeys and Applied Marks on 1 July 2026), AJ Park, Smart & Biggar (which absorbed Ridout & Maybee and Bereskin & Parr) and ROBIC, IPH services 26 IP jurisdictions from 26–27 offices in ten countries. It claims the No.1 patent position in Australia, Canada, Indonesia, New Zealand, the Philippines and Singapore, and the No.1 trade mark position in Australia, Canada and New Zealand. Revenue is largely recurring and annuity-like, built on long patent life cycles. About 37% of revenue is billed in USD against a negligible USD cost base. After a decade of acquisition-led growth, IPH is now in an execution phase: integrating brands, deploying AI in patent workflows and reviewing its long-term strategic positioning under a new CEO.
What IPH does
IPH is a holding company for professional IP-services firms ("member firms"). The member firms employ registered patent attorneys, trade mark attorneys, IP lawyers and technical specialists. Their work covers:
Patent services: drafting, filing (including PCT national-phase entry), prosecution (responding to examiner reports), grant, annuity/renewal management, oppositions and litigation support.
Trade mark services: clearance searching, filing, prosecution, oppositions, renewals and enforcement.
Designs: registration and prosecution.
IP litigation and advisory: primarily in Canada (Smart & Biggar, ROBIC) and through Griffith Hack and Spruson & Ferguson in Australia.
Digital/automated trade mark filing: the Applied Marks platform for SMEs and sole traders, now operated within Griffith Hack.
Company's own description (paraphrased from the FY26 Annual Report and results release)
IPH describes itself as the leading international IP services group. Its network of member firms operates out of 27 offices, services more than 25 IP jurisdictions, and employs more than 1,700 people across Australia, Canada, China, Hong Kong SAR, Indonesia, Malaysia, New Zealand, the Philippines, Singapore and Thailand. The FY26 Investor Presentation adds annual volumes of 32,000+ patent filings and 15,000+ trade mark filings (cases filed or instructed to be filed worldwide, internal data).
Business and revenue model
| Revenue element | Description | Character |
|---|---|---|
| Professional service fees | Activity-based scale fees (filing, examination request, acceptance/grant) plus hourly charges (responses to examiner reports, advice, litigation) | Service; semi-recurring because each patent family generates a multi-year fee stream |
| Recoverable disbursements | Official fees and foreign-agent fees passed through to clients. Offset by "agent fee expenses" (FY26: $184.8m). | Pass-through, low/no margin |
| Renewals/annuities | Recurring renewal fees over patent life (up to 20 years from the PCT filing date) | Recurring |
| Litigation | Canadian IP litigation (Smart & Biggar, ROBIC) and Australian enforcement | Variable, case-flow dependent (FY25 litigation revenue fell as cases settled) |
| Digital trade mark filing | Applied Marks online platform, with fixed-fee pricing to SMEs | Productised service |
There is no material product, subscription or licensing revenue. The software business WiseTime (formerly Practice Insight) was divested in July 2022.
Patent life-cycle economics (FY26 Investor Presentation, p.38): A foreign applicant typically files in its home patent office. It files a PCT international application within 12 months and enters the Australian national phase at about 31 months. Grant typically follows 2.5–3.5 years after national-phase entry. Renewals can then run to year 20. More than half of Australian patent applications each year are PCT national-phase entries. This produces a long revenue tail, but it also means that falls in international (especially US-origin) PCT filings show up in IPH revenue with an 18–30 month lag.
Value-chain position
IPH sits at the "local associate" node of the global IP value chain:
-
Innovator (corporation, university, SME) →
-
Home-market IP firm (often a US, European, Japanese, Korean or Chinese firm acting as the instructing "associate") →
-
Secondary-market local agent (IPH member firm) files and prosecutes in Australia, NZ, Canada, Singapore and other Asian markets →
-
National IP office (IP Australia, IPONZ, CIPO, IPOS, DGIP, IPOPHL and others).
Much of IPH's work is therefore referral-based, coming from foreign associate firms rather than directly from end-clients. This makes relationships with US and other foreign firms, and the cross-referral network, central assets. IPH reports 1,330 cumulative cross-referrals between its Canadian and Asia-Pacific firms over the five years to FY26.
Customer types and end-markets
| Customer type | Examples / notes |
|---|---|
| Foreign associate IP firms | US, European, Japanese, Korean and Chinese firms instructing local filings. The US accounts for ~30–35% of Australian patent filings by origin (FY26 presentation). |
| Multinational corporations (direct) | Large filers in Singapore. IPH "acts for a number of the most significant filers" there. |
| Domestic innovators | Australian, NZ and Canadian corporates, universities, research institutes, government agencies |
| SMEs and sole traders | Trade mark filings through Applied Marks |
| Litigants | Canadian pharma and life-sciences litigation (Smart & Biggar, ROBIC) |
End-markets (technology fields): pharmaceuticals and life sciences, biotech, medical devices, chemicals, engineering, ICT/software, energy and clean-tech, and consumer brands (trade marks). IPH does not publish a revenue split by technology field (ND).
Independent characterisation
IPH is best understood as a roll-up of high-margin, regulated professional-services franchises in mid-sized IP jurisdictions. It is funded by strong cash conversion (FY26: 110%) and modest debt (leverage 1.8x). Its competitive moat is local regulatory accreditation, brand reputation, scale-driven efficiency and the associate-referral network. Its structural vulnerability is dependence on inbound international filings, particularly from the US, combined with emerging disruption:
-
Self-filed provisional patent applications in Australia rose from 1,228 (FY22) to 6,894 (FY26), plausibly reflecting AI-enabled and lower-cost filing behaviour.
-
Generative AI is compressing drafting and prosecution effort, and with it hourly-fee pools.
-
National IP offices are being modernised (the CIPO system disruption in Canada is one example).
Group results since FY23 show acquisition-driven top-line growth with declining organic momentum in ANZ and margin compression. Underlying EBITDA margin fell from 34.3% (FY23, calc.) to 28.9% (FY26). The investment case has therefore shifted from "consolidator" to "operator/transformer".
Strategy
Stated strategy (FY26 Investor Presentation, new CEO)
| Theme | Components |
|---|---|
| 1. "Accelerate Sustainable Growth" | Increase client connectivity across IPH; drive enterprise-wide business development; use client, market and portfolio data better; expand service delivery capability |
| 2. "Simplify and Scale the Platform" | Integrate systems and processes; improve operating efficiency and consistency; strengthen working capital and cost discipline; capture integration and transformation benefits |
| 3. "Build Future Capability" | Scale adoption of AI and automation; strengthen technology and data capability; invest in talent and leadership development |
| In parallel | A review of IPH's long-term strategic positioning and of opportunities to create greater value through its international platform |
The new CEO set out three enterprise priority themes. Wording below is paraphrased except for short theme titles.
FY27 priorities (FY26 presentation):
-
Sustainable organic growth through deeper client engagement.
-
Maximising the international platform to win work from the US, Europe, China, Japan and Korea.
-
Greater cross-firm collaboration and referrals.
-
Investment in people and capability.
-
Harnessing technology, data and AI.
-
Disciplined execution and operational excellence.
Strategic initiatives, last 24 months
| Initiative | Announced | Details | Status / targets |
|---|---|---|---|
| Corporate cost reduction program | 2H FY25 | Streamlined corporate functions and restructured the leadership team | Target $8–10m annualised savings from FY26; $5.1m of corporate savings achieved in FY26 |
| Transformation function | HY25 (Feb 2025) | Group transformation function to drive operational efficiency | Transformation project costs $3.0m FY26 (includes AI deployment) |
| AI deployment (Harvey AI, AI agents) | FY25–FY26 | Drafting and prosecution assistance; inbound enquiry automation; AI framework and governance | 220+ users; 46,000+ queries; 1,600+ matters; up to 75% efficiency on test cases |
| Cyber uplift program | Post-2023 incident | Three-year, NIST-aligned | FY26 maturity target met; completion CY2026 |
| Brand simplification | Apr 2026 onward | Pizzeys into Griffith Hack; Applied Marks into Griffith Hack | Completed 1 Jul 2026; brands reduced from seven to five |
| Canadian integration | 2023–2025 | Ridout & Maybee and Bereskin & Parr into Smart & Biggar; pricing harmonisation | Synergies above target (FY25 commentary) |
| ERP / HRIS / AP automation | FY25–FY26 | ERP implementation in Canada; group HRIS; AP automation | Ongoing |
| Business development refocus | FY25–FY26 | ANZ: primary markets outside the US and second-tier US associates. Asia: corporates filing into China and outbound regional filings. Group: Western Europe, Japan, South Korea and Chinese inbound filings. | Case transfers: 5,674 (ANZ) and 3,242 (Asia) in FY26 |
| Capital management | Feb 2025 and Mar 2026 | Buy-backs: $74.2m (FY25); up to 12.2m shares from Mar 2026 ($18.7m and 5.4m shares by 30 Jun 2026) | Ongoing |
| Dividend policy reset | 20 Aug 2026 | FY27 onward: 70–90% payout of statutory EPSA (previously 80–90% of cash-adjusted NPAT) | Effective FY27 |
| Sustainability | FY26 | First AASB S2 climate-related disclosures; fourth GHG calculation; first global DEI baseline survey (~70% participation); "Reflect" Reconciliation Action Plan | Ongoing |
Medium-term financial targets and guidance
Earnings guidance: IPH does not provide quantitative earnings guidance. The HY25 materials stated no forward-looking outlook statements were given, and FY26 materials contained qualitative priorities only.
Leverage: maximum target of up to 2.0x net debt/EBITDA (facility basis).
Dividend: 70–90% of statutory EPSA from FY27.
Qualitative operating expectation: the remaining CIPO backlog is expected to clear over the next 12 months (FY26 presentation).
Products & Services
IPH sells professional services, not products. The "catalogue" below is organised by member-firm brand and service line.
ANZ segment
| Brand / offering | Founded | Description and capabilities | Target customer | Pricing model | Latest status |
|---|---|---|---|---|---|
| Spruson & Ferguson (Australia) | 1,887 | Full-service patent and TM firm covering patent drafting, PCT national phase, prosecution, oppositions, TM portfolio management and designs. Strong in pharma, biotech, engineering and ICT. | Foreign associates (US, Europe, Asia), Australian corporates and research institutions | Scale fees plus hourly | Core brand; Australian No.1 patent filer within the group |
| Griffith Hack | 1,904 | Patents, TMs, designs, enforcement, IP strategy and commercialisation. Absorbed Watermark (2020), Shelston IP (Xenith era)†, Pizzeys (1 Jul 2026) and the Applied Marks platform (1 Jul 2026). | Associates, corporates, universities, SMEs | Scale fees plus hourly | Expanded inbound-associate practice post-Pizzeys. Ranked in IAM Patent 1000 2026, Managing IP IP Stars 2026 and WIPR Leaders 2026 (firm communications). |
| Applied Marks (within Griffith Hack) | 2,008 | Online automated TM application platform: guided self-service filing with attorney oversight. A leading filer in the Australian TM register by volume. | SMEs, sole traders, early-stage innovators | Fixed-fee online packages (amounts ND) | Integrated into Griffith Hack 1 Jul 2026; its MD continues as General Manager |
| Pizzeys (retired brand) | 1,981 | Inbound IP practice with strong relationships with international associates; also a Singapore presence | International associates | Scale fees | Brand retired 1 Jul 2026; Pizzeys brand-name impairment of $1.3m in FY26 |
| AJ Park (New Zealand) | — | Full-service NZ IP firm covering patents, TMs, designs, enforcement and commercialisation. No.1 in NZ patents and TMs per company. | NZ corporates, foreign associates | Scale fees plus hourly | Core NZ brand (2 NZ offices) |
Asia segment
| Brand / offering | Description and capabilities | Coverage | Target customer | Notes |
|---|---|---|---|---|
| Spruson & Ferguson Asia | Patent and TM prosecution, oppositions, searches, renewals; translation-intensive filing | Singapore, Malaysia, Indonesia, Thailand, Philippines, Hong Kong SAR, China (Beijing) | Multinationals filing regionally; Chinese inbound and outbound filers | No.1 patent filer in Singapore (18.8% share FY26), Indonesia and the Philippines. Won the 2026 Gawad Yamang Isip award (top patent filer in the Philippines, 2025) and the DGIP One Decade Performance Award (top patent filer in Indonesia, 2015–2024). |
| Pizzeys Singapore (legacy) | Singapore patent filing | Singapore | Associates | Counted in IPH's Singapore market share |
| Regional coverage services | Coordination of filings into Vietnam and other emerging ASEAN markets | Vietnam and others | Associates | FY26 presentation shows filing data for Vietnam |
FY26 operating metrics (Asia): 3,242 case transfers secured (2,000+ trade marks, 900+ patents, 200+ designs). IPH filings outside Singapore fell 4.3% against a strong FY25 (+16.5%).
Canada segment
| Brand / offering | Founded | Description and capabilities | Target customer | Notes |
|---|---|---|---|---|
| Smart & Biggar | ND (historic Canadian IP firm) | Canada's largest IP firm, covering patents, TMs, IP litigation (pharma/life-sciences, notably regulatory and patent-linkage proceedings), copyright and regulatory work. Absorbed Ridout & Maybee (2023) and Bereskin & Parr (Mar 2025). | Global pharma, technology multinationals, foreign associates, Canadian corporates and universities | No.1 patent filer and No.1 TM filer in Canada (FY26 presentation). Pre-acquisition market share ~16% (Livewire, 2022). |
| ROBIC | 1,892 | Largest IP firm in Quebec (220+ staff at acquisition). The IP agency is owned by IPH; the associated law practice is held through a Quebec LLP in compliance with Quebec regulation. Patents, TMs, litigation, francophone capability. | Quebec and francophone clients; European (especially French-speaking) associates | Filed 3,000+ patents and 1,500+ TMs in 2022 (at acquisition) |
| Bereskin & Parr (merged) | 1,965 | Toronto-based IP firm with offices in Mississauga, Waterloo and Montreal; 2,800+ patent filings in 2023 | Corporates, universities, government agencies | Merged into Smart & Biggar, Mar 2025 |
| Ridout & Maybee (merged) | — | Canadian IP firm | Associates and corporates | Merged into Smart & Biggar, 2023 |
Group-level capabilities and platforms
| Capability | Description | Status (FY26) |
|---|---|---|
| AI-assisted drafting and prosecution | Harvey AI and other tools for patent drafting and prosecution workflows | 220+ active practitioners, 46,000+ AI queries, 1,600+ patent matters processed, up to 75% efficiency gain on initial test cases |
| Virtual AI agent | Automates high-volume inbound enquiry and instruction processing | Deployed and replicated across multiple member firms |
| Core AI framework and governance | Pilot → prove → scale → standardise process; responsible-AI policies; human accountability retained | Established FY26 |
| Group ERP and HRIS | ERP implementation in Canada; group HRIS; accounts-payable automation | IT SaaS implementation costs of $1.7m in FY26 |
| Cyber uplift program | NIST-aligned three-year roadmap run by a group information security team | FY26 maturity target achieved; completion expected in CY2026 |
Financial Narrative
Sources: FY22 Results Announcement (18 Aug 2022); FY23 Appendix 4E (17 Aug 2023) and Lawyers Weekly coverage of FY23 results; FY24 data as reported in the FY25 Results Announcement comparatives; FY25 Results Announcement (21 Aug 2025); FY26 Results Announcement and Investor Presentation (20 Aug 2026).
Definitional notes:
-
"Total revenue" means revenue and other income excluding interest income (the company's headline measure from FY24).
-
"Underlying NPAT" in FY22–FY23 was defined on a basis equivalent to today's "Underlying NPATA", i.e. excluding amortisation of acquired intangibles. FY24 underlying NPAT ($112.4m) equals FY24 underlying NPATA, so the series is presented as one row.
-
FY22 Underlying EBITDA ($137.4m) predates the FY23 change to include share-based payments; it is not fully comparable.
Income statement
Dividend detail:
-
FY23: interim 15.5c, final 17.5c (35% franked).
-
FY24: final 19.0c (30% franked); implied interim 16.0c.
-
FY25: interim 17.0c (20% franked), final 19.5c (30% franked).
-
FY26: interim 19.0c (20% franked), final 19.5c (30% franked).
Margins and growth
-
Revenue CAGR FY23–FY26 (total revenue, 3 years): ~12.8% (calc.).
-
Statutory revenue CAGR FY22–FY26 (4 years): ~17.4% (calc., using statutory revenue for FY22 and the revenue line for FY26).
-
Underlying EBITDA CAGR FY22–FY26: ~10.6% (calc.; FY22 basis not fully comparable).
Balance sheet
Detailed balance sheet data are disclosed in the FY26 Investor Presentation for 30 June 2025 and 30 June 2026.
Short/long-term debt split: IPH presents borrowings as a single line. The facility maturity profile at 30 June 2026 shows the drawn debt maturing across FY27–FY29 (approximately $110.6m, $96.8m and $274.4m of drawn/total facility tranches in the presentation chart). The $210m refinanced in December 2025 now matures December 2028. Undrawn facilities, including guarantees and overdrafts, were $104.7m. A precise current/non-current split is ND in the sources reviewed.
Net tangible assets per share: FY23 -$0.96; FY22 -$0.01 (FY23 Appendix 4E). Net tangible assets are negative because of the acquisition-heavy balance sheet.
Cash flow: notes and sources
Note: the FY26 final dividend alone equates to ~$50.0m. The cash component of dividends paid net of the dividend reinvestment plan is ND.
Commentary on trends, inflections and drivers
1. Growth regime change. FY22–FY25 revenue growth was overwhelmingly inorganic: Smart & Biggar from FY23, Ridout & Maybee and ROBIC from FY24, Bereskin & Parr from FY25. Total revenue rose ~43% between FY23 and FY25. FY26 marks the end of the acquisition tailwind. With no new deals and only ~3 months of incremental Bereskin & Parr contribution, reported revenue grew just 0.4%.
2. Margin compression. Underlying EBITDA margin fell ~7pp from FY22 to FY26 for three reasons:
-
Mix shift to Canada, which runs at ~26% margin against historical ANZ and Asia margins in the mid-30s to low-40s.
-
ANZ operating deleverage as US inbound filings fell.
-
Inflationary employment and IT/cyber costs.
The FY25 cost program ($8–10m annualised target; $5.1m of corporate savings realised in FY26) stabilised the margin at ~29%.
3. Statutory-versus-underlying gap narrowing. Non-underlying costs fell from $17.1m (FY24) to $13.2m (FY25) to $6.6m (FY26), and amortisation of acquired intangibles is rolling off as ANZ customer-relationship assets become fully amortised. As a result, statutory NPAT is converging toward underlying NPAT, and statutory EPS rose 19.7% in FY26. This is the basis for the new FY27 dividend policy anchored to statutory EPSA.
4. Per-share dilution and repair. The August 2024 $125m equity raise lifted the weighted average share count by 9.8% in FY25, so EPSA fell 2.3% despite NPATA growth of 7.3%. Buy-backs of $74.2m in FY25 and $18.7m in FY26 have since reduced the share count. EPSA recovered to 47.2c in FY26 (+4.2%).
5. Cash generation is the bright spot. Free cash flow reached $135.9m in FY26 (+18.3%), helped by a $17.6m working-capital release and capex of only $2.9m. On a market capitalisation of ~$850m this is a FCF yield of ~16% (calc.), which underpins the ~11–12% dividend yield.
6. Balance sheet shrinkage is mostly FX. Intangibles fell $114.7m in FY26: $61.9m from FX translation (stronger AUD against CAD), $51.4m from amortisation, and a $1.3m Pizzeys brand impairment. Equity fell $77.1m through the buy-back and a $43.3m decline in the FX translation reserve.
7. FX sensitivity. About 37% of revenue is billed in USD against negligible USD costs. A one-cent move in AUD/USD changes revenue by ~A$2.8m. The AUD appreciated 4.7% against the USD and 3.9% against the CAD on average in FY26, which turned like-for-like EBITDA growth of +2.9% into a reported decline of 0.6%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue from ordinary activities, statutory (AUD Mn) | 374.3 | 482.9 | — | 706.2 | 710.4 |
Total revenue incl. other income ex-interest (AUD Mn) | — | 496.3 | 609.9 | 710.3 | 712.8 |
Agent fee expenses (AUD Mn) | — | — | — | 182.7 | 184.8 |
Net revenue after agent fees (AUD Mn, calc.; gross-profit proxy) | — | — | — | 527.6 | 528.0 |
Employee benefits expense (AUD Mn) | — | — | — | 261.6 | 264.8 |
Other operating expenses (AUD Mn) | — | — | — | 58.8 | 57.3 |
Underlying EBITDA (AUD Mn) | 137.4 | 170.0 | 195.5 | 207.2 | 205.9 |
Statutory EBITDA (AUD Mn) | — | — | — | 186.4 | 196.5 |
Depreciation & amortisation (AUD Mn) | — | — | — | 72.1 | 66.8 |
Underlying EBIT (AUD Mn; operating-income proxy) | — | — | — | 135.1 | 139.1 |
Net finance costs (AUD Mn) | — | — | — | 24.7 | 23.9 |
Underlying pre-tax profit (AUD Mn, calc.) | — | — | — | 110.4 | 115.2 |
Underlying income tax (AUD Mn) | — | — | — | 28.4 | 28.2 |
Underlying NPAT, post-amortisation (AUD Mn) | — | — | — | 82.0 | 87.0 |
Underlying NPATA, legacy "Underlying NPAT" for FY22–FY23 (AUD Mn) | 86.7 | 99.0 | 112.4 | 120.6 | 122.7 |
Non-underlying expenses, net of tax (AUD Mn) | — | — | 17.1 | 13.2 | 6.6 |
Statutory NPAT (AUD Mn) | 52.6 | 64.5 | 60.8 | 68.8 | 80.4 |
Statutory basic EPS (A cents) | — | — | 25.1 | 25.8 | 30.9 |
Statutory diluted EPS (A cents) | 24.0 | — | — | — | — |
Underlying basic EPSA (A cents) | — | — | 46.4 | 45.3 | 47.2 |
Dividends per share, total (A cents) | 30.5 | 33.0 | 35.0 | 36.5 | 38.5 |
Margin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Underlying EBITDA margin (%) | 35.7 | 34.3 | 32.1 | 29.2 | 28.9 |
Underlying EBIT margin (%, calc.) | — | — | — | 19.0 | 19.5 |
Statutory net margin (%, calc. on total revenue) | — | 13.0 | 10.0 | 9.7 | 11.3 |
Underlying NPATA margin (%, calc.) | — | 19.9 | 18.4 | 17.0 | 17.2 |
Total revenue growth (%) | — | — | 22.9 | 16.5 | 0.4 |
Underlying EBITDA growth (%) | 11 | 24 | 15 | 6.0 | -0.6 |
Like-for-like Underlying EBITDA growth (%) | 2 | — | — | -3.9 | 2.9 |
Balance Sheet and Financial Ratios (x)
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
Total assets (AUD Mn) | — | 1,350.9 | 1,208.4 |
Cash & cash equivalents (AUD Mn) | — | 59.0 | 59.8 |
Trade & other receivables (AUD Mn) | — | 174.0 | 167.9 |
Contract assets / WIP (AUD Mn) | — | 33.1 | 25.4 |
Intangibles incl. goodwill (AUD Mn) | — | 1,006.8 | 892.1 |
Right-of-use assets (AUD Mn) | — | 46.8 | 35.6 |
Borrowings, balance sheet (AUD Mn) | — | 413.4 | 374.7 |
Gross debt, facility basis (AUD Mn) | — | 415.3 | 376.3 |
Lease liabilities (AUD Mn) | — | 56.3 | 41.4 |
Net debt, ex-leases (AUD Mn) | 359.9 | 356.3 | 316.5 |
Total liabilities (AUD Mn) | — | 651.5 | 586.1 |
Total equity (AUD Mn) | — | 699.4 | 622.3 |
Net working capital (AUD Mn) | — | 172.2 | 154.6 |
Leverage, facility basis (x) | — | 1.9 | 1.8 |
Cash Flow and Margin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Operating cash flow pre-financing and tax (AUD Mn) | — | — | — | 192.7 | 216.4 |
Cash conversion, EBITDA to gross operating cash flow (%) | — | — | — | 103.4 | 110.1 |
Income taxes paid (AUD Mn) | — | — | — | 37.6 | 41.8 |
Net interest paid (AUD Mn) | — | — | — | 21.4 | 23.2 |
Operating cash flow (AUD Mn) | — | — | — | 133.7 | 151.4 |
Capex (AUD Mn) | — | — | — | 7.9 | 2.9 |
Finance lease payments (AUD Mn) | — | — | — | 10.9 | 12.6 |
Free cash flow, company definition (AUD Mn) | — | — | — | 114.9 | 135.9 |
Share buy-backs (AUD Mn) | 0 | 0 | 0 | 74.2 | 18.7 |
Equity raised, before costs (AUD Mn) | 0 | — | 0 | 125.0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY25 | FY26 | Basis |
|---|---|---|---|
ROE, statutory (%) | — | 12.2 | calc.: NPAT / average equity |
ROE, underlying NPATA (%) | — | 18.6 | calc. |
ROA (%) | — | 6.3 | calc.: NPAT / average total assets |
ROIC, underlying EBIT after tax / (net debt + equity) (%) | — | 10.8 | calc.: 139.1 × (1 − 0.245) / (316.5 + 622.3) |
Debt / equity (x) | 0.59 | 0.60 | calc.: borrowings / equity |
Net debt / underlying EBITDA (x) | 1.72 | 1.54 | calc.; facility-basis leverage is 1.9x and 1.8x |
Interest coverage, underlying EBIT / net finance costs (x) | 5.5 | 5.8 | calc. |
Asset turnover (x) | — | 0.56 | calc.: total revenue / average assets |
Free cash flow / net debt (%) | 32 | 43 | calc. (company presents this inverted as 3.1x and 2.3x) |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY24 (agg.) | FY25 (company) | FY26 (company) |
|---|---|---|---|
Canada (Americas) | 196 | 293.3 | 318.5 |
Australia & New Zealand | 295 | 310.6 | 285.6 |
Asia | 122 | 120.7 | 120.4 |
Region revenue growth (%)
| Region revenue growth (%) | FY25 (company vs agg. FY24; indicative only) | FY26 reported | FY26 like-for-like |
|---|---|---|---|
Canada | 49.6 | 8.6 | 5.8 |
Australia & New Zealand | 5.3 | -8.0 | -4.2 |
Asia | -1.1 | -0.2 | 2.6 |
Currency Details
| Currency | Share of service revenue |
|---|---|
USD | ~37% (FY25: 38%) |
CAD, AUD, EUR, NZD, SGD, other | Remainder. Exact percentages shown only graphically (ND). |
Destination Region Details
| Destination region | Share of IPH patent cases filed or instructed (%) |
|---|---|
Australia | 33 |
Canada | 32 |
Asia | 25 |
New Zealand | 7 |
Rest of world | 3 |
Operating Metrics (number) and Revenue by Region (%)
| Indicator | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Singapore patent market filings (number) | 14,569 | 13,289 | 13,190 | 13,435 |
IPH share of Singapore patent filings (%) | 21.9 | 21.1 | 21.9 | 18.8 |
Operating Metrics (number) and Revenue by Region (%) (FY22–FY25)
| Indicator | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
Australian patent filings, standard (number) | 31,819 | 30,785 | 30,608 | 29,152 |
Australian self-filed provisional filings (number) | 1,228 | 1,278 | 1,301 | 2,008 |
IPH share of Australian patent filings (%) | 34.0 | 32.4 | 31.7 | 29.3 |
Share Price & Returns
| Reference point | Share price (AUD) | Source / note |
|---|---|---|
Early Sep 2026 (latest verified) | 3.26–3.37 | InvestSMART quotes |
20 Aug 2026, pre-FY26 result | 4.22 | Price at release |
52-week range (to Aug 2026) | 3.07–5.15 | Kalkine |
Late Aug 2025 | ~4.58–4.80 | Director purchase prices |
Aug 2024 placement | 6.00 | Bereskin & Parr scrip price |
Nov 2023 | 6.91 | ROBIC scrip price |
52-week high, May 2023 | 8.36 | InvestSMART |
Oct 2022 (Smart & Biggar era) | ~10+ | Implied by broker targets of $10.63–11.95 (FNArena) |
Performance (approx., calc.) | Return (%) | — |
1-year (Sep 2025 → Sep 2026, price only) | ~ -30 | — |
3-year (Sep 2023 → Sep 2026, price only; vs ~$6.9–8.4 range) | ~ -55 | — |
Valuation Multiples
| Multiple | IPH (calc.) | Peer comparison |
|---|---|---|
P/E, statutory (FY26 EPS 30.9c) | 10.7x | Listed IP-services peers not available (QANTM delisted); ND |
P/E, underlying EPSA (47.2c) | 7.0x | — |
EV / underlying EBITDA (EV ~A$1,162m) | 5.6x | Smart & Biggar was acquired at ~10x EV/EBITDA (2022) |
EV / sales | 1.63x | — |
P/B (equity $622.3m) | 1.36x | — |
Dividend yield (38.5c) | 11.7% | — |
FCF yield (FCF $135.9m) | ~16% | — |
Dividend (A cents per share)
| Dividend (A cents per share) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Interim | — | 15.5 | 16.0 | 17.0 | 19.0 |
Final | — | 17.5 | 19.0 | 19.5 | 19.5 |
Total | 30.5 | 33.0 | 35.0 | 36.5 | 38.5 |
Capital Programmes
| Program | Period | Shares | Amount |
|---|---|---|---|
On-market buy-back #1 | Feb–Jun 2025 | 15.9m cancelled | $74.2m |
On-market buy-back #2 | From 9 Mar 2026 | Up to 12.2m authorised; 5.4m bought by 30 Jun 2026 | $18.7m to 30 Jun 2026; ongoing |
Analyst Conclusions
Management guidance
-
No quantitative FY27 earnings guidance.
-
Qualitative expectations:
-
The CIPO backlog should clear over the next 12 months.
-
The ANZ cost base will continue to be "right-sized".
-
Asian business development momentum continues.
-
AI scale-up proceeds.
-
The strategic positioning review will be updated "in due course".
-
-
New dividend policy for FY27: 70–90% of statutory EPSA.
Consensus expectations
Post-FY26 consensus revenue and EPS forecasts are ND. A third-party aggregator (multiples.vc) presented forward EBITDA growth assumptions in the mid-single digits, but these could not be validated and are not relied upon.
Bull case
-
Canadian earnings inflection. Like-for-like EBITDA rose 11.8% in FY26 with margin up 1.4pp. Release of the CIPO backlog (strong May–June 2026 Notices of Allowance) could add a further step-up in FY27, and Canada already provides 37% of segment EBITDA.
-
Deep value with self-funded returns. At ~5.6x EV/EBITDA, ~7x P/EPSA, an ~11.7% dividend yield and a
16% FCF yield, the market prices in structural decline. FCF of $135.9m comfortably covers dividends ($99m at 38.5c) and an ongoing buy-back while leverage falls. -
AI as a margin lever plus a value-crystallising review. A CEO with AI-rollout credentials, combined with demonstrated efficiency gains of up to 75%, could rebuild margins toward the low-30s. The strategic review could unlock value through portfolio actions or corporate interest at a premium to a depressed multiple.
Bear case
-
Structural ANZ decline. IPH's Australian share fell from 34.0% to 24.1% in four years. ANZ EBITDA fell 14.4% in FY26, and ANZ is still the largest EBITDA contributor at 42%. Continued erosion could offset Canadian gains.
-
AI cannibalisation. The 5.6x jump in self-filed provisionals since FY22 suggests that low-cost and AI-enabled filing is eroding the entry level of the patent funnel. AI efficiency may have to be shared with clients through lower fees rather than retained.
-
Stagnant per-share value creation. EPSA was roughly flat over FY24–FY26 (46.4c to 47.2c) despite more than $200m of Canadian M&A and $125m of new equity. Underlying EBITDA fell in FY26, and the AUD's strength against the USD and CAD remains a persistent headwind.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| 2026 AGM and possible strategy update | 17 Nov 2026 | Early findings of the CEO's strategic review; trading update |
| HY27 results | ~Feb 2027 | ANZ like-for-like trend (gap vs market), Canadian CIPO revenue, Asia growth, cost savings |
| Strategic review outcome | FY27 | Portfolio changes, capital allocation, M&A or divestment |
| CIPO backlog clearance | Through 2H CY2026 – 1H CY2027 | Canadian revenue acceleration |
| US PCT filing trend | Ongoing | National-phase entries into Australia and NZ |
| AUD/USD and AUD/CAD | Ongoing | ~A$2.8m of revenue per 1c AUD/USD move |
| Buy-back execution | Ongoing | Remaining capacity of ~6.8m shares |
| Bereskin & Parr scrip escrow expiry | ~Sep 2026 | Potential selling overhang |
| AI productivity metrics | HY27 / FY27 | Margin conversion of efficiency gains |
| Index re-inclusion or further exits | Quarterly rebalances | Liquidity and passive flows |
Analyst verdict
IPH enters FY27 at an inflection point both strategically and in sentiment. Ten years of acquisition-led growth built a genuinely differentiated asset: the leading multi-jurisdiction IP-services platform focused on secondary markets, with No.1 positions in six patent jurisdictions, highly recurring workflows and exceptional cash conversion. That growth model has run its course. FY26 revenue was flat, underlying EBITDA slipped and the margin has compressed by almost seven percentage points since FY22, while the ANZ core keeps losing share to market shifts the company does not control.
The market has responded by de-rating IPH to distressed-looking multiples. The stock trades at roughly 5.6x EV/EBITDA and 7x underlying earnings, with a dividend yield near 12%, after a ~20% fall on the FY26 result and removal from the ASX 200. At these levels the valuation implies continuing structural decline. Yet the evidence is mixed rather than terminal:
-
Canada is now the largest segment and is growing like-for-like at double digits at the EBITDA line.
-
Asia has returned to growth.
-
Statutory earnings and free cash flow rose strongly in FY26.
-
Leverage is falling, even with buy-backs.
The swing factors are execution under a new CEO and the economics of AI. If O'Malley can convert AI productivity into retained margin, stabilise ANZ market share and use the strategic review to simplify the portfolio or surface value, today's price could prove a cyclical trough for a cash-rich franchise. If AI and self-filing instead commoditise the patent funnel faster than IPH adapts, the high yield may be a value trap financed by a shrinking earnings base.
On balance, IPH is a high-yield, deep-value special situation with elevated execution risk. The key near-term tests are the AGM on 17 November 2026 and the HY27 ANZ like-for-like trend.
SOURCES (primary unless noted)
1: IPH FY26 Results Announcement, ASX: https://announcements.asx.com.au/asxpdf/20260820/pdf/072z4bdbvv66xf.pdf — 20 Aug 2026
2: IPH FY26 Results Investor Presentation, ASX: https://announcements.asx.com.au/asxpdf/20260820/pdf/072z4lxsm4hgw6.pdf — 20 Aug 2026
3: IPH Appendix 4E and FY26 Annual Report, ASX: https://announcements.asx.com.au/asxpdf/20260820/pdf/072z461zpp1957.pdf — 20 Aug 2026
4: IPH FY25 Results Announcement, ASX: https://announcements.asx.com.au/asxpdf/20250821/pdf/06n41x1twq4r4y.pdf — 21 Aug 2025
5: IPH HY26 Results Announcement (via Webull bulletin mirror) — 19 Feb 2026
6: IPH FY23 Appendix 4E, ASX: https://announcements.asx.com.au/asxpdf/20230817/pdf/05sq88t0m7j232.pdf — 17 Aug 2023
7: IPH FY22 Results Announcement, ASX: https://www.asx.com.au/asxpdf/20220818/pdf/45czf9bqwj9tlk.pdf — 18 Aug 2022
8: IPH CEO appointment announcement, ASX: https://announcements.asx.com.au/asxpdf/20260528/pdf/0701g11rz32nhc.pdf — 28 May 2026
9: IPH CEO commencement announcement — 1 Jul 2026
10: IPH Completion of Bereskin & Parr, ASX: https://announcements.asx.com.au/asxpdf/20240930/pdf/068gr9n1j8flj9.pdf — 30 Sep 2024
11: Cassels Brock deal notes (ROBIC, Bereskin & Parr) — 2023–2024
12: Business News Australia (Ridout & Maybee, ROBIC, Smart & Biggar values) — 2023
13: Lawyers Weekly (FY23 results; cyber incident) — 18 Aug 2023
14: The Lawyer Magazine AU (Pizzeys / Griffith Hack; Applied Marks integration; CEO appointment) — 2026
15: InvestSMART, MarketScreener, Kalkine, Motley Fool AU (prices, board register, aggregator segment data). Secondary sources. — 2025–2026
16: FilingReader (Citigroup and JPMorgan substantial holder notices). Secondary source. — Dec 2025
17: Capital Brief (Blattman retirement) — Nov 2025
18: Livewire Markets and FNArena (Smart & Biggar valuation, 2022 broker targets). Secondary sources. — 2022
All figures are in A$ unless stated otherwise.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Education | Age | Remuneration |
|---|---|---|---|---|---|---|
Anthony (Tony) O'Malley | Managing Director & CEO | From 1 Jul 2026 | 30+ years in global professional services across Big Four firms, major law firms and corporates. Most recently Global Legal Business Solutions Leader at PwC (legal network in 100+ territories, ~4,000 people). Led evaluation and rollout of generative-AI platforms. Board chair of law firm Wotton Kearney. | — | — | Total fixed remuneration A$950,000 p.a. STI weighted 50% financial / 50% non-financial. LTI per plan (28 May 2026 announcement). |
Dr Andrew Blattman | Former MD & CEO (to 30 Jun 2026); transitional support to 30 Nov 2026 | CEO Nov 2017 – Jun 2026; ~30 years with the group | 22+ years at Spruson & Ferguson before becoming CEO | PhD (field ND) | — | FY25 statutory remuneration ND in sources reviewed. Bought 92,788 shares (~$442k) on 27 Aug 2025. |
Brendan York | Chief Financial Officer | ~Jun 2025 – present (per MarketScreener) | — | — | 47 (MarketScreener) | — |
Tan Tee | Group technology leader (listed by MarketScreener as Chief Technology Officer) | ~Dec 2017 – present† | — | — | — | — |
Fiona Darlington | Group HR leader | ~Oct 2023 – present† | — | — | — | — |
Tamsyn Hoff | Company Secretary | — | — | — | — | — |
Aaron Le Poidevin | Managing Director, Griffith Hack (member-firm level) | — | — | — | — | — |
Matthew Zischka | Managing Director, Smart & Biggar (member-firm level) | — | — | — | — | — |
Stuart Wood | Canadian Regional CEO (appointed at the Bereskin & Parr acquisition, Aug 2024) | From 2024 | Canadian professional-services background | — | — | — |
Board of Directors
| Name | Role | Appointed | Independence | Other roles and background |
|---|---|---|---|---|
Peter Warne | Non-Executive Chairman | Director Nov 2021; Chair from early 2022 | Independent | Chair of Argo Investments, Argo Global Listed Infrastructure and Virgin Australia Holdings. NED of UniSuper, Allens and the Financial Markets Standards Board. Former Chair of Macquarie Group (2016–2022), former ASX director, former Chair of OFX and ALE Property. Age ~70 (MarketScreener). |
Anthony (Tony) O'Malley | Managing Director & CEO | 1 Jul 2026 | Executive | See above |
John Atkin | Non-Executive Director | 23 Sep 2014 | Not independent (former IPH CEO†; longest-serving director) | Chairman of Qantas Superannuation (in wind-up); Vice Chair of Outward Bound International; former director of Aurizon, Integral Diagnostics and GPT Metro |
Vicki Carter | Non-Executive Director | 5 Oct 2022 | Independent | ND in sources reviewed. On-market purchases Feb 2025 and Nov 2025. |
David Wiadrowski | Non-Executive Director | 15 Nov 2023 | Independent | ND in sources reviewed. On-market purchases Aug 2025. |
Kate Mason | Non-Executive Director | 1 Sep 2025 | Independent | Elected at the Nov 2025 AGM. Purchased 14,300 shares (Dec 2025) and 19,880 shares at $3.32 (1 Sep 2026). |
Jingmin Qian | Non-Executive Director (present at Nov 2025 AGM) | — | Independent | Not listed on the September 2026 board register; current status ND |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
~Jun 2025 | Brendan York becomes CFO | Part of the corporate restructure |
2H FY25 | Corporate services and leadership team restructured | $8–10m annualised cost-out program |
1 Sep 2025 | Kate Mason appointed NED | Board renewal |
6 Nov 2025 | Blattman announces retirement | Board began an internal and external search |
28 May 2026 | O'Malley appointed CEO effective 1 Jul 2026 | Followed a global search; transformation and AI credentials emphasised |
1 Jul 2026 | O'Malley commences; Blattman leaves the board | Appendix 3X and 3Z lodged |
1 Jul 2026 | 33 group promotions, including 15 new Principals | Talent pipeline |
Major Shareholders
| Holder | Stake | Date / notice | Notes |
|---|---|---|---|
Citigroup Global Markets Australia and related bodies | 5.80% | Became substantial 5 Dec 2025 | Largely securities lending and custody-related |
JPMorgan Chase & Co. and affiliates | 5.32% (13.9m shares) | Became substantial ~22 Dec 2025; ceased shortly after (late Dec, per MarketScreener) | Mainly securities lending |
Marathon Asset Management | Change in substantial holding | 27 Jul 2026 | Stake level ND |
Unnamed holder (change notice) | — | 23 Feb 2026 | Previous notice dated 20 Mar 2024 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Ownership | Positioning vs IPH |
|---|---|---|---|
ANZ | QANTM IP: Davies Collison Cave, FPA Patent Attorneys, Collison & Co† | Private (Adamantem Capital, since Aug 2024) | Main Australian scale rival; delisted, so private-equity-backed consolidation may intensify |
ANZ | Phillips Ormonde Fitzpatrick (POF) | Private partnership | Strong Melbourne-based patent firm |
ANZ | Wrays | Private | Perth-headquartered national patent and TM firm |
ANZ | Baxter IP, Madderns, AJ Pietras and other mid-tier firms | Private | Price competition in patents and TMs |
ANZ | Law firms with IP practices (Allens, Corrs, King & Wood Mallesons) | Partnerships | IP litigation and advisory |
ANZ (NZ) | James & Wells, Baldwins (part of the Spruson-competing NZ market)† | Private | NZ patent and TM competition |
Asia | Marks & Clerk (Singapore, Malaysia, Hong Kong) | Private-equity-backed | Regional prosecution rival |
Asia | Davies Collison Cave Asia (QANTM) | Private | Singapore and Malaysia rival |
Asia | Tilleke & Gibbins | Private | Strong in Thailand, Vietnam, Indonesia |
Asia | Drew & Napier, Rajah & Tann, Dentons Rodyk, Amica Law | Partnerships | Singapore law-firm IP practices |
Asia | Rouse | Private-equity-backed | Asia IP services and brand protection |
Canada | Gowling WLG | Partnership | Major Canadian IP practice |
Canada | Norton Rose Fulbright Canada, Borden Ladner Gervais, Osler, Fasken | Partnerships | Full-service firms with IP and litigation teams |
Canada | Marks & Clerk Canada | Private-equity-backed | Patent prosecution rival |
Canada | Aird & McBurney, Torys and other mid-tier firms | Partnerships | Niche competition |
Global tech/IP services | Clarivate (incl. CPA Global), Dennemeyer, Questel | Listed (Clarivate, NYSE) / private | Renewals, annuity management, IP software; compete for portfolio-management spend |
Disruptors | AI drafting and self-filing tools; national office e-filing portals | Various | Erode low-complexity work; visible in the Australian self-filed provisionals surge |
Competitor Detail
| Metric | IPH (FY26) |
|---|---|
Revenue | A$712.8m |
Revenue growth | 0.4% reported; 1.6% like-for-like |
Underlying EBITDA margin | 28.9% |
R&D / technology intensity | ~0.9% (calc., tech/transformation non-underlying) |
Recent Developments
Member firms act as counsel in client matters; for example, Griffith Hack acted in Republic of Peru v Registrar of Trade Marks [2026] FCA 791, a certification trade mark registrability case.



